Hit by surprise setback, AstraZeneca scrambles to explain why its two-in-one COPD inhaler was beaten by GSK rival
AstraZeneca was expecting a Phase IIIb trial to put its two-in-one COPD inhaler on top of GlaxoSmithKline’s rival product. Instead, it was hit by a troubling setback.
The company reported that while Bevespi Aerosphere (glycopyrronium/formoterol fumarate) didn’t do worse than GSK’s Anoro (umeclidinium/vilanterol) on peak forced expiratory volume in one second (FEV1), it didn’t do better either. And on trough FEV1, the other co-primary endpoint, AstraZeneca’s inhaler performed worse.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.